Gemlapodect

Gemlapodect
Clinical data
Other namesNOE-105; NOE105
Routes of
administration		Oral[1]
Drug classPhosphodiesterase PDE10A inhibitor
Identifiers
  • 1-methyl-4-(morpholine-4-carbonyl)-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-5-carboxamide
CAS Number
PubChem CID
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H21N7O3
Molar mass431.456 g·mol−1
3D model (JSmol)
  • CN1C(=C(C=N1)C(=O)N2CCOCC2)C(=O)NC3=CC4=NC(=NN4C=C3)C5=CC=CC=C5
  • InChI=1S/C22H21N7O3/c1-27-19(17(14-23-27)22(31)28-9-11-32-12-10-28)21(30)24-16-7-8-29-18(13-16)25-20(26-29)15-5-3-2-4-6-15/h2-8,13-14H,9-12H2,1H3,(H,24,30)
  • Key:MMCSMWHWVGGCGL-UHFFFAOYSA-N

Gemlapodect (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name NOE-105) is a phosphodiesterase PDE10A inhibitor which is under development for the treatment of Tourette's syndrome and speech disorders.[1][2][3] It is taken orally.[1] The drug is thought to work by modulating dopaminergic signaling in the striatum through PDE10A inhibition in medium spiny neurons.[3] Gemlapodect was originated by Roche and is under development by Noema Pharma.[1][2] As of September 2025, it is in phase 2 clinical trials for both Tourette's syndrome and speech disorders.[1][2]

See also

References

  1. ^ a b c d e "Noema Pharma". AdisInsight. 18 September 2025. Retrieved 2 June 2026.
  2. ^ a b c "Delving into the Latest Updates on Gemlapodect with Synapse". Synapse. 10 March 2026. Retrieved 2 June 2026.
  3. ^ a b Häge A, Krämer R, Dunlap M, Mechler K, Müller-Vahl KR, Nagy P (June 2025). "Emerging therapeutic approaches for Tourette syndrome and other tic disorders - a systematic review of current clinical trials". European Child & Adolescent Psychiatry. 34 (6): 1719–1729. doi:10.1007/s00787-024-02637-x. PMID 39714607.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.